Qiagen, a sample to insight molecular testing company, has joined forces with Centogene, owners of CentoMD. CentoMD is the largest mutation database for rare diseases in the world. By collaborating the two companies hope to develop quick and easy to use kits to diagnose rare diseases.
At present the patient journey for many rare disease patients is arduous and long. Part of this comes from the fact that there are no easy or quick tests to perform to diagnose a definitive disease. With CentoMD already possessing a line of their own genetic testing kits, I believe that Qiagen could help make these simpler to use and provide a better defined supply chain to a wider population. This will not only aid patients but also doctors, and health services in general to diagnose and streamline care for these patients.
"By combining deep, expertly curated resources from Qiagen and Centogene, we will deliver powerful insights for researchers and clinicians and ultimately help patients and families deal with rare and hereditary disorders."